News

Complete data are now available from the first stage of the trial, in which patients were randomized 1:2 to receive high-dose cytarabine alone (standard therapy control group) or

The pre-specified primary efficacy endpoint of change in hemolysis was achieved with an 86% reduction. Key secondary endpoints including fatigue and transfusions/anemia were also achieved. In the Aegis

This single-center, double-blind, placebo-controlled, single-ascending dose trial tested the safety, tolerance and pharmacokinetics of a single intravenous administration of NU206, in 32 healthy male volunteers. Participants were enrolled

Dr Schottelius joins MorphoSys from Genentech, South San Francisco, where he served as the director of immunology, tissue growth and repair early development and most recently as medical

Approximately more than 800 subjects have been enrolled in the independent, blind, multicenter study. The company estimates that four to six weeks will be required to allow its

In addition to the new US headquarters facility, Patheon has opened a new pharmaceutical development laboratory in Research Triangle Park. This laboratory will support Patheon’s current US-based pharmaceutical

This study will explore the safety, tolerability and pharmacokinetics of subcutaneous (SC) administration of a bisphosphonate plus recombinant human hyaluronidase enzyme (rHuPH20). Currently, injectable bisphosphonates must be administered

Under the agreement, Symbollon will transfer ownership of its patent application covering use of its technology in the upper respiratory tract. As partial consideration under the agreement, Symbollon

CS-866AZ is a combination drug of the long-acting calcium channel blocker azelnidipine (Calblock jointly researched and developed by Daiichi Sankyo and its partner Ube Industries) and the high